Figure 4From: Clinical significance of SOX9 in human non-small cell lung cancer progression and overall patient survivalKaplan-Meier curves with univariate analyses (log-rank) for patients with low SOX9-expressing (bold line) versus high SOX9-expressing tumors (dotted line). The cumulative 3-year survival rate was 65.9% in the low SOX9 expression group (n = 44), whereas it was only 24.5% in the high SOX9 expression group (n = 45).Back to article page